275 Armand-Frappier Boulevard
Laval, QC H7V 4A7
450 680 4500
Full Time Employees: 74
|Mr. Roberto Francesco Bellini||Pres, CEO & Director||790.35k||N/A||1980|
|Mr. Ramzi Benamar||Chief Financial Officer||650.48k||N/A||1973|
|Dr. Andreas Orfanos FFPM, M.B.B.Ch, MBA||Chief Operating Officer||417.58k||N/A||1959|
|Dr. Denis Garceau Ph.D.||Chief Scientific Officer||496.56k||N/A||1957|
|Dr. Catherine M. Bonuccelli M.D.||Chief Medical Officer||741.66k||N/A||1958|
|Mr. Daniel Matthews||Director of Investor Relations & Communications||N/A||N/A||N/A|
|Mr. Tony Matzouranis||Chief Bus. Officer||N/A||N/A||1973|
|Mr. Sebastien Roy||Corp. Sec.||N/A||N/A||1976|
BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada.
BELLUS Health Inc.’s ISS Governance QualityScore as of June 1, 2023 is 10. The pillar scores are Audit: 4; Board: 9; Shareholder Rights: 6; Compensation: 10.